Kythera Faces Advisory Committee Meeting For Double Chin Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
The California biotech faces one last hurdle before potential approval of its double chin injectable ATX-101 when it comes in front of the FDA’s dermatology advisory committee.
You may also be interested in...
Kythera Doubles Down On Double Chins With Bayer Buyback
The biotech buys back rights to its own drug after attaining a more advantageous financial position and successful late-stage results.
Kythera Readies NDA For Double Chin Drug ATX-101
The specialty pharma is preparing a new drug application for its lead product candidate, hoping the demand for drugs like wrinkle-reducing toxins will translate to the submental fat market.
Deals Of The Week: Pfizer/FoldRx, Takeda/Orexigen, Bayer/Kythera ...
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.